Efficacy of Probiotic Therapy on Atopic Dermatitis in Adults Depends on the C-159T Polymorphism of the
Atopic dermatitis
C-159T polymorphism
Cytokines
Probiotics
Journal
Open access Macedonian journal of medical sciences
ISSN: 1857-9655
Titre abrégé: Open Access Maced J Med Sci
Pays: North Macedonia
ID NLM: 101662294
Informations de publication
Date de publication:
15 Apr 2019
15 Apr 2019
Historique:
received:
14
02
2019
revised:
22
03
2019
accepted:
23
03
2019
entrez:
4
5
2019
pubmed:
3
5
2019
medline:
3
5
2019
Statut:
epublish
Résumé
The C-159T polymorphism of the The purpose of the study was to investigate the efficacy of adding probiotic ( The study included 37 adult patients with AD. There were identified 19 patients with exogenous (IgE-dependent) and 18 with endogenous (IgE-dependent) AD. To evaluate the efficacy of the probiotics all patients were divided into three groups for both exogenous and endogenous AD. The first group was selected from patients with CC genotype (C-159T) who received standard therapy (ointment of fluticasone propionate 0.005% - 2 times a day, emollients - 2 times a day) and probiotic ( The results of our study found that the addition of probiotics ( Simultaneous determination of the exogenous or endogenous form, identification of the C-159T genotypes, evaluation of the serum level of IL-4 and TGF-β can serve as an algorithm for the personalised treatment of patients with atopic dermatitis.
Sections du résumé
BACKGROUND
BACKGROUND
The C-159T polymorphism of the
AIM
OBJECTIVE
The purpose of the study was to investigate the efficacy of adding probiotic (
MATERIAL AND METHODS
METHODS
The study included 37 adult patients with AD. There were identified 19 patients with exogenous (IgE-dependent) and 18 with endogenous (IgE-dependent) AD. To evaluate the efficacy of the probiotics all patients were divided into three groups for both exogenous and endogenous AD. The first group was selected from patients with CC genotype (C-159T) who received standard therapy (ointment of fluticasone propionate 0.005% - 2 times a day, emollients - 2 times a day) and probiotic (
RESULTS
RESULTS
The results of our study found that the addition of probiotics (
CONCLUSION
CONCLUSIONS
Simultaneous determination of the exogenous or endogenous form, identification of the C-159T genotypes, evaluation of the serum level of IL-4 and TGF-β can serve as an algorithm for the personalised treatment of patients with atopic dermatitis.
Identifiants
pubmed: 31049080
doi: 10.3889/oamjms.2019.242
pii: OAMJMS-7-1053
pmc: PMC6490491
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1053-1058Références
Am J Respir Cell Mol Biol. 1999 May;20(5):976-83
pubmed: 10226067
Am J Respir Crit Care Med. 2001 Mar;163(4):965-9
pubmed: 11282774
Pediatr Allergy Immunol. 2003 Aug;14(4):255-60
pubmed: 12911501
Am J Respir Crit Care Med. 2004 Mar 1;169(5):615-22
pubmed: 14617510
Allergy. 2004 May;59(5):520-5
pubmed: 15080833
J Invest Dermatol. 2005 Oct;125(4):659-64
pubmed: 16185263
J Allergy Clin Immunol. 2006 Sep;118(3):658-65
pubmed: 16950285
J Nutr. 2007 Mar;137(3 Suppl 2):756S-72S
pubmed: 17311973
Clin Exp Allergy. 2007 Apr;37(4):498-505
pubmed: 17430345
J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 2:S156-9
pubmed: 18685504
Am J Respir Crit Care Med. 2009 Feb 1;179(3):186-93
pubmed: 19029003
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2159-64
pubmed: 20080669
Am J Rhinol Allergy. 2010 Jan-Feb;24(1):e1-3
pubmed: 20109306
BMC Med Genet. 2011 Jul 11;12:93
pubmed: 21745379
Int J Immunopathol Pharmacol. 2011 Oct-Dec;24(4):1037-48
pubmed: 22230409
Dis Markers. 2013;35(6):765-71
pubmed: 24347797
J Am Acad Dermatol. 2014 Oct;71(4):814-21
pubmed: 24906613
Clin Exp Allergy. 2015 Apr;45(4):779-87
pubmed: 25600169
Br J Dermatol. 2016 Oct;175(4):678-86
pubmed: 27012805
Mol Nutr Food Res. 2017 Jan;61(1):
pubmed: 27500859
Allergy. 2016 Dec;71(12):1662-1665
pubmed: 27716946
J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682
pubmed: 29676534
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8034-8041
pubmed: 30536353
Endocr Metab Immune Disord Drug Targets. 2019;19(3):373-381
pubmed: 30574857
Iran J Otorhinolaryngol. 2019 Jan;31(102):1-9
pubmed: 30783593